|
TRANSGENE's expertise in gene therapy may help it transform into a cancer fighter. The biotech company is focusing its research and development efforts on its two most promising cancer vaccine candidates. One uses two antigens from the human papillomavirus (HPV) to treat cervical cancer, while the other candidate targets breast, lung, prostate, lung, and other cancers. In addition to these two projects, TRANSGENE is developing two immune therapy adjuvants that are injected directly into tumors in addition to other cancer therapy products. Contract research and licensing revenues account for all of the company's profit. Chairman Christophe Mérieux and his family control 70% of TRANSGENE.
|
| | | Contact Information | |
Address: |
11 rue de Molsheim
67082 Strasbourg Cedex, France
| | Phone: | +33-3-88-27-91-00 | | Fax: | +33-3-88-22-58-07 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 3.10 M | | Employees (2008): | 186 |
|
|
Key People
| | • |
Chairman:
Michel Dubois
| | • |
CEO and Director:
Philippe Archinard
| | • |
VP and CFO:
Philippe Poncet
|
|
|
